05.11.21 Clinical Trial Software And Service Partners Ready To Help
With the exponential number and increasing complexity of clinical studies now being run the paper-based informed consent process is inherently inefficient. Rave eConsent is an innovative, patient-friendly, electronic informed consent and patient enrollment system for clinical trials.
Our industry is now, more than ever, ready to move to decentralized trials (DCT) and design hybrid protocols that support trial continuity and have a more patient-centric approach. Most sponsors have struggled to implement DCT and need an innovative, modern technology platform that enables more efficient and future-ready trial processes. The unique architecture of encapsia brings the technology to the data and provides an agile, revolutionary way to support decentralized clinical trial.
As COVID-19 response initiatives and vaccine rollouts begin to bring the pandemic under control, we consider what changes to clinical trials will be made permanent.
Top of mind for Rob Church, a pharmaceutical and biotechnology regulatory law expert at US firm, Hogan Lovells, is the future of clinical studies, particularly in light of the decentralized clinical trial (DCT) trend seen over the past year.
The pandemic has been the catalyst in speeding up the wider adoption of DCTs, with sponsors using electronic remote informed consent, remote outcomes assessments, and, in some cases, remote administration of a study drug, and home health visits by clinical study staff, he told us
Avance Clinical to Present Decentralized Trials - No Going Back for Oracle Health Sciences Connect
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference.
Avance Clinical CEO Yvonne Lungershausen, shared the company s insights on the future of Decentralized Clinical Trials (DCTs) and the technology and patient factors that will determine success. Avance Clinical uses the full range of eClincial technologies to support clients wanting DCTs or a site-based approach while still leveraging advance technology including ePro, eSource and eConsent.
ADELAIDE, AU, Apr 22, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference.
Title: Decentralized Trials - No Going Back
Link: https://www.oracle.com/in/industries/life-sciences/health-sciences-connect/sessions/
Time: 23 April, 2021 - 3.05 pm (Australia/Adelaide ACST).
Avance Clinical CEO Yvonne Lungershausen, shared the company s insights on the future of Decentralized Clinical Trials (DCTs) and the technology and patient factors that will determine success. Avance Clinical uses the full range of eClincial technologies to support clients wanting DCTs or a site-based approach while still leveraging advance technology including ePro, eSource and eConsent.